Profit From The Race For A Zika Vaccine

08/09/2016 06:55 AM
Source: Investing.com
by: Investment U

We’re talking about investing in an indispensable $24 billion industry.

As much as people hate getting shots, the risk of serious illness has a funny way of propelling us toward the nearest doctor’s office.

Historically, vaccine manufacturers perform well during health crises. Take, for example, the meningitis outbreak of 2015. Sanofi (PA:SASY), the company behind the meningitis vaccine Menactra, started the year with a $44.55 share price. By August, the stock was worth $53.48. A 20% jump.

Now to combat Zika, two companies have joined forces...

Inovio Pharmaceuticals Inc (NASDAQ:INO) and GeneOne Life Science Inc (KS:011000) just announced that their Zika vaccine has been approved for a Phase 1 human trial. Year to date, Inovio shares are up 55%. And the stock should continue to gain with every piece of positive news.

For the complete article please visit Investing.com

ABOUT
Dynamic Wealth Research was founded on the principle the world is changing at an ever-increasing pace. The greatest profit opportunities an investor will ever find are from massive, sweeping changes. Dynamic Wealth Research analyzes and closely follows these changes, keeps its readers on the leading edge of them, and shows you how to be best positioned these anxious, interesting, and ultimately profitable times.